SRR25617882
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.320
- OXIDATIVE_PHOSPHORYLATION+0.160
- DNA_REPAIR+0.120
- MYC_TARGETS_V1+0.120
- ESTROGEN_RESPONSE_EARLY+0.080
- E2F_TARGETS+0.040
- MITOTIC_SPINDLE+0.000
- PROTEIN_SECRETION+0.000
- HEME_METABOLISM-0.020
- UNFOLDED_PROTEIN_RESPONSE-0.030
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.550
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_GAMMA_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- INFLAMMATORY_RESPONSE-0.400
- COAGULATION-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
- HEDGEHOG_SIGNALING-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A0TR-01A-11R-A084-07 | — | B | 0.919 |
| 2 | GSM5359423 | — | — | 0.913 |
| 3 | R16 | — | — | 0.912 |
| 4 | TCGA-LQ-A4E4-01A-11R-A266-07 | — | B | 0.902 |
| 5 | SRR1456841 | GTEX | — | 0.899 |
| 6 | SRR1385036 | GTEX | — | 0.898 |
| 7 | SRR655864 | GTEX | — | 0.897 |
| 8 | SRR1429307 | GTEX | — | 0.895 |
| 9 | SRR1472621 | GTEX | — | 0.894 |
| 10 | SRR35579800 | — | B | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |